Established Medical Therapy for Benign Prostatic Hyperplasia

Auffenberg, Gregory B.; Helfand, Brian T.; McVary, Kevin T.

doi:10.1016/j.ucl.2009.07.004

Cited by 102 publications

(87 citation statements)

References 89 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…as shown in table (1). The identified SNPs were substitution polymorphisms, in the first one, nucleotide A in control men replace with nucleotide T in BPH patients while, nucleotide T in control men replaced with nucleotide A in BPH patients, these two polymorphisms were found in 3 and 2 from the ten patients (30% and 20% ) respectively.…”

Section: Introduction:-mentioning

confidence: 96%

“…Benign prostatic hyperplasia (BPH), is a hyperplastic process of the fibromuscular stromal and glandular epithelial elements within the prostatic transition zone (Auffenberg, 2009). As the most common benign tumor found in men, it comes in the fourth series of the most common disease, after coronary disease, hypertension and diabetes (Roehrborn, 2011).…”

Section: Introduction:-mentioning

confidence: 99%

See 1 more Smart Citation

Single Nucleotide Polymorphisms (Snps) in Page Family Member 4 (Page4) Gene in Men With Benign Prostate Hyperplasia From Iraq.

Sattar¹,

Ameery²,

Shaibani³

2017

IJAR

View full text Add to dashboard Cite

Section: Introduction:-mentioning

confidence: 96%

Section: Introduction:-mentioning

confidence: 99%

Single Nucleotide Polymorphisms (Snps) in Page Family Member 4 (Page4) Gene in Men With Benign Prostate Hyperplasia From Iraq.

Sattar¹,

Ameery²,

Shaibani³

2017

IJAR

View full text Add to dashboard Cite

“…1,2 The enlarged prostate contributes to voiding symptoms and irritative symptoms. 3 It was reported that the α1A-alpha receptors subtype is predominant in the prostate but recent studies have detected the expression of both α 1A-and α 1D-alpha receptors in human prostate tissue.…”

Section: Introductionmentioning

confidence: 99%

Comparing the effect of Alpha blocker (Silodosin) and Phosphodiesterase type 5 inhibitor (Tadalafil) in benign prostate hyperplasia patients with lower urinary tract symptoms: a single centre study

Singh¹,

Biswas²,

Mittal³

et al. 2018

Int Surg J

View full text Add to dashboard Cite

Background: Benign prostatic hyperplasia (BPH) is a histologic diagnosis that refers to the proliferation of smooth muscle and epithelial cells within the prostatic transition zone. The aim of this systematic review is to determine the comparative effectiveness and safety of phosphodiesterase 5 inhibitors (PDE5-Is) and alpha blockers used alone or in combination for the treatment of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH).Methods: We analyzed 54 patients of BPH with LUTS with baseline IPSS, Qmax and PVR over one-year period. They were randomized equally in three groups i.e. group receiving alpha blocker, group receiving phosphodiesterase 5 inhibitors and group receiving combination of the two drugs. These patients were followed up at the end of 1st month and 3rd month and IPSS, Qmax and PVR was compared.Results: Out of 54, 45 patients completed the study. At the end of the study all the three groups showed significant improvement in IPSS, PVR and Qmax, all p <0.05, but the combination group showed much better improvement in terms of percentage. Two patients on alpha blockers had episode of hypotension.Conclusions:Thus, we summarize that phosphodiesterase 5 inhibitors should be preferred over alpha blockers in patients with LUTS/BPH as it has, firstly, outcome similar to alpha blockers. Secondly, have no documented side effect. Third, can be given in any patient, irrespective of the fact that whether the patient is suffering from erectile dysfunction or not.

show abstract

“…[1,2] Garraway et al reported that the prevalence of BPH was 25.3% in total 699 subjects aged between forty and seventy and tended to increase as the age increased. [3,4] Erectile Dysfunction (ED) is defined as difficulty in gaining or keeping erected state enough to enjoy sex life.…”

Section: Introductionmentioning

confidence: 99%

Pharmacokinetics and safety profiles of tadalafil/tamsulosin HCl fixed-dose combination capsule under fasted and fed condition in healthy volunteers

Jin

Yoo

et al. 2016

Transl Clin Pharmacol

View full text Add to dashboard Cite

Co-administration of tadalafil and tamsulosin HCl in patients with benign prostate hyperplasia and erectile dysfunction is increasing in clinical settings. Development of fixed-dose combination (FDC) of tadalafil and tamsulosin HCl could contribute to improving patients' adherence and treatment efficacy. We evaluated the pharmacokinetics and safety profiles of a newly developed fixed-dose combination capsule of tadalafil 5 mg/tamsulosin HCl 0.4 mg in comparison with co-administration of each formulation in healthy volunteers under fasted and fed conditions. Two randomized, openlabel, single-dose, two-way, crossover studies were completed in 29 subjects under fasted condition, and 33 subjects under fed condition. Serial blood sample collection for PK analysis was conducted up to 72 hours after dosing, and PK parameters were calculated using non-compartmental analysis. Geometric mean ratios and 90% confidence intervals of the C max and AUC last were used to evaluate comparative bioavailability. In both fasted and fed condition studies, the bioequivalence was established. The most common adverse drug reactions were orthostatic hypotension and headache with no statistical difference between treatment groups. All subjects with orthostatic hypotension recovered at follow-up test. Although changes in vital signs from baseline were statistically significant, there were no subjects with systolic blood pressure < 90 mmHg and there were no clinically meaningful signs or symptoms associated. FDC of tadalafil and tamsulosin HCl can be an alternative to co-administration of individual drugs for providing better compliance. Changes in blood pressure should be kept in mind when tadalafil and tamsulosin HCl are co-administered in clinical settings.

show abstract

Established Medical Therapy for Benign Prostatic Hyperplasia

Cited by 102 publications

References 89 publications

Single Nucleotide Polymorphisms (Snps) in Page Family Member 4 (Page4) Gene in Men With Benign Prostate Hyperplasia From Iraq.

Single Nucleotide Polymorphisms (Snps) in Page Family Member 4 (Page4) Gene in Men With Benign Prostate Hyperplasia From Iraq.

Comparing the effect of Alpha blocker (Silodosin) and Phosphodiesterase type 5 inhibitor (Tadalafil) in benign prostate hyperplasia patients with lower urinary tract symptoms: a single centre study

Pharmacokinetics and safety profiles of tadalafil/tamsulosin HCl fixed-dose combination capsule under fasted and fed condition in healthy volunteers

Contact Info

Product

Resources

About